Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter ...
The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses ...
Well-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers ...
With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of ...
Teva Pharmaceuticals is the 'stalking horse bidder' to kick off the auction process for BioXcel Therapeutics' AI-derived ...
Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other ...
Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would ...
Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its ...
Lisraya carries a boxed warning typical of JAK inhibitors, but otherwise has a broad label that allows use in all adults with ...
The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival ...
The FDA granted the approval of Revolution Medicines' daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma ...
AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results